Silence Therapeutics has asked the U.K. High Court of Justice to rule on an intellectual property dispute with Alnylam and The Medicines Company.
The delisting plan of Chinese vaccine maker Sinovac has been complicated by a bribery case and a new bid.
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
The FDA's rejection of Coherus BioSciences' biosimilar version of Amgen's Neulasta means that 51 people at the company will lose their jobs.
It’s time again to call on you to nominate your Fierce 15 for 2017.
ImmunoCellular Therapeutics has suspended a phase 3 trial of its lead cancer vaccine after failing to raise the funds it needs to complete the study.
Idorsia has spun out of Actelion after Johnson & Johnson wrapped up its $30 billion takeover of the Swiss biotech.
Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.
Mersana Therapeutics is capitalizing on a buoyant period with a filing for a $75 million IPO to advance its antibody-drug conjugates (ADCs) for cancer through…
Deciphera Pharmaceuticals will head to ASCO this week with a spring in its step after raising $52 million in a third-round financing.
The CEO of Akari Therapeutics has quit amid a probe into the release of phase 2 data and a related analyst report.